** Shares of Applied Therapeutics APLT.O fall 80.3% to $1.70 after the bell
** Company says the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic metabolic disease
** The FDA's letter to the company said the marketing application for the drug, govorestat, cannot be approved in its current form, due to certain deficiencies - APLT
** Galactosemia can cause neurological complications, including deficiencies in speech, cognition, behavior and motor skills
** Up to last close, stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。